INVEGA SUSTENNA® delays time to relapse vs a group of commonly prescribed daily pills
This finding is from a study designed to see how INVEGA SUSTENNA®, a once-monthly injection, compared to a group of 7 commonly prescribed daily oral pills in adults living with schizophrenia who had recently been in jail
The study wasn’t designed to compare INVEGA SUSTENNA® to each individual oral pill. However, it was intended to reflect the real-life issues that many adults living with schizophrenia may experience in their daily lives, by selecting participants who are often excluded from studies.
Read more about the relapse prevention benefits of INVEGA SUSTENNA® below, and talk with your doctor about whether this monthly product may be right for you.
How was the study set up?
A group of 444 adults living with schizophrenia were selected to participate in this 15-month study. These adults were often excluded from trials due to recent histories of arrest and jail time, prior self-reported substance or alcohol abuse, or who are currently homeless.
They were then divided into 2 treatment groups: 1 group took the once-monthly injection INVEGA SUSTENNA®, and the other group continued taking 1 of the 7 most common daily pills (aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, or risperidone) prescribed by their doctor.
The rate of relapse was studied among these participants over 15 months. Relapse was defined as admission to a psychiatric hospital, arrests or jail time, suicide, quitting treatment due to safety or side effects, stopping or adding treatment because it wasn’t working, or seeking additional help to prevent hospitalization.
What was learned from the study?
At 15 months, patients in the INVEGA SUSTENNA® group experienced fewer relapses and a longer time to their first relapse compared to patients in the daily pills group.
RATE OF RELAPSE
MOST COMMONLY PRESCRIBED DAILY PILLS
RATE OF RELAPSE
What were the common side effects seen in this study?
Injection-site Pain Insomnia
DAILY ORAL PILLS
Other common side effects seen in previous studies with INVEGA SUSTENNA® include:
- Restlessness/needing constant movement
- Abnormal muscle movements including tremors (shaking), shuffling, uncontrolled involuntary movements, and abnormal eye movements
Please see Important Safety Information below for additional information.
Remember, your doctor is the best person to decide what treatment is appropriate for you, considering your medical and treatment history. Talk to your doctor about your options to treat schizophrenia.
References: 1. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board–blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561.
2. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ. IMS Real-World Data. May 2010-December 2013.
3. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2019